Abstract | PURPOSE: EXPERIMENTAL DESIGN: Female strain A mice (7-8 weeks of age) were given 100 mg/kg benzo(a)pyrene [B(a)P] by i.p. injection, and 4 or 14 weeks later, they were given 50 or 100 mg/kg R115777 by oral gavage 5 days/week. The mice were sacrificed 22 weeks after they received the B(a)P. RESULTS:
Tumor multiplicity was 5.0 +/- 0.85, 4.5 +/- 0.52, 2.1 +/- 0.31, and 1.5 +/- 0.31 tumors/mouse in mice that received 0, 50, 100 (weeks 4-22), or 100 (weeks 14-22) mg/kg R115777. Thus, 100 mg/kg R115777 was similarly effective in preventing lung tumors when administered during the promotional phase of carcinogenesis [that is, either 4 or 14 weeks after B(a)P], whereas the lower dose of 50 mg/kg R115777 was ineffective. The proliferating cell nuclear antigen labeling index was also significantly reduced in lung tumors from mice treated with 100 mg/kg R115777 starting at 4 or 14 weeks. CONCLUSIONS: These results demonstrated that R115777 can prevent the development of lung tumors in the A/J mouse model, where tumors routinely have mutations in the Ki-Rasoncogene.
|
Authors | William T Gunning, Paula M Kramer, Ronald A Lubet, Vernon E Steele, David W End, Walter Wouters, Michael A Pereira |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 9
Issue 5
Pg. 1927-30
(May 2003)
ISSN: 1078-0432 [Print] United States |
PMID | 12738751
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antineoplastic Agents
- Enzyme Inhibitors
- Quinolones
- Benzo(a)pyrene
- Alkyl and Aryl Transferases
- p21(ras) farnesyl-protein transferase
- tipifarnib
|
Topics |
- Alkyl and Aryl Transferases
(antagonists & inhibitors)
- Animals
- Antineoplastic Agents
(therapeutic use)
- Benzo(a)pyrene
(toxicity)
- Chemoprevention
- Enzyme Inhibitors
(therapeutic use)
- Female
- Lung Neoplasms
(chemically induced, prevention & control)
- Mice
- Mice, Inbred A
- Quinolones
(therapeutic use)
|